The plan could dramatically shift the mission of the space agency, prioritizing low-Earth orbit activity over distant exploration.
Read more
Health before semantics
Posted in biotech/medical, life extension
Let’s debate whether ageing is a disease *after* the diseases of old age are eliminated, shall we?
Whether or not ageing ought to be considered a disease is still matter of controversy, both among experts and laypeople. Particularly, the latter tend to turn up their noses at the thought of ageing being pathological and not ‘normal’, especially if they’re outside the life-extension/rejuvenation community. Clearly, they ignore the fact that ‘normal’ and ‘pathological’ aren’t mutually exclusive at all. It’s perfectly normal to suffer from hear loss in old age; notwithstanding, it is out of the question that hear loss is a pathology and we have developed several ways to make up for it. It presently can’t be cured, because like all age-related diseases, it can only get worse as long as the age-related damage that causes it keeps accumulating.
In my humble opinion of quasi-layperson (I’m nowhere near being an expert, but I do think I know about ageing more than your average Joe), whether or not ageing is a disease is merely a matter of semantics, depending largely on what we want to label as ‘ageing’—not to mention how we define ‘disease’.
If we say that ‘ageing’ is the set of age-related pathologies that affect a given person, then ageing isn’t a disease any more than a box of crayons is itself a crayon. Nonetheless, if you have a box of crayons then you have a bunch of crayons; if you have ageing as we defined it, then you have a bunch of diseases, and the grand total of your ailments doesn’t change whether you consider ageing as a disease as well or not. Quite frankly, I’d pick the box of crayons over ageing any time.
Read more
Some small write-ups out today on the NY Times piece coverig transhumanism, including in The Paris Review, a well known literary publication for writing folks out there: https://www.theparisreview.org/blog/2017/02/09/touch-someone…ther-news/ &
http://transhumanist-party.org/2017/02/10/nyt-magazine-zoltan/ &
In today’s arts and culture news roundup: Nan Goldin on the first photographer she loved; the transhumanist search for sexbots; singing “Ode to Joy”; & more.
Brogan BamBrogan has jumped back into the race to transform transportation. The engineer, who left Hyperloop One amid a wild legal battle last summer, has launched his own effort to build a network of tubes and pods to fling people about the planet at near-supersonic speeds. It’s called Arrivo (Italian for “arrived”), and it plans to put you—or at least your stuff—in a working hyperloop in just three years.
As CEO, BamBrogan (yes, that’s his legal name) says the new Los Angeles–based company has lined up funding and is in talks to produce hyperloop systems for a variety of clients. Without revealing where those projects are, he says he plans to start by moving cargo, a good way to prove the system works and iron out the kinks without killing anybody, all while bringing in some revenue.
BamBrogan is a respected engineer who spent years at SpaceX before cofounding Hyperloop One with venture capitalist Shervin Pishevar in 2014. In July, he and three coworkers sued the company, alleging shenanigans like breach of fiduciary duty, violating labor laws, wrongful termination, and infliction of emotional distress. Hyperloop One countersued, accusing BamBrogan et al. of an attempted mutiny. In November, the aggrieved parties reached a confidential settlement and dropped the suits, which involved details like an overpaid fiancée, drunken shouting, a nightclub bouncer, and … um … a noose.
Read more
Summary:
- Many recent advances in artificial intelligence and aging biomarkers that transpired since 2013 are converging
- Gachon University and Gil Medical Center are at the forefront of aging research in Korea
- Aging research is gaining credibility in the pharmaceutical industry and healthcare in general
- Insilico Medicine and Gachon University and Gil Medical Center have partnered to collaboratively develop biomarkers and interventions
Friday, 3rd of February, 2017, Baltimore, MD — Insilico Medicine today announced that it signed a Memorandum of Understanding (MOU) and started the first collaborative research project with one of the largest research and medical networks, Gachon University and Gil Medical Center. The intent of the long-term collaboration is to develop artificially intelligent multimodal biomarkers of aging and health status as well as interventions intended to slow down or even reverse the processes leading to the age-related loss of function.
Read more
I suggest they connect with DARPA or Dr Phillip Ball on QBS.
This is undoubtedly relief for certain medical conditions, but the potential for misuse, harm and control demands an ethical debate to define the limits. Unfortunately, Technocrats shun such discussions. ⁃ TN Editor.
In labs testing how brain implants could help people with physical disabilities, tales of success can be bittersweet.
Experiments like those that let a paralyzed person swig coffee using a robotic arm, or that let blind people “see” spots of light, have proven the huge potential of computers that interface with the brain. But the implanted electrodes used in such trials eventually become useless, as scar tissue forms that degrades their electrical connection to brain cells (see “The Thought Experiment”).
Nice forum on QC Crystal Superconduction in Mar.
From March 8–10, 2017, an International Conference on Crystal Growth is to be held in Freiburg under the auspices of the German Association of Crystal Growth DGKK and the Swiss Society for Crystallography SGK-SSCR. The conference, jointly organized by the Fraunhofer Institute for Solar Energy Systems ISE, the Crystallography department of the Institute of Earth and Environmental Sciences at the University Freiburg and the University of Geneva, is to be held in the seminar rooms of the Chemistry Faculty of the University of Freiburg. Furthermore, the Young DGKK will hold a seminar for young scientists at Fraunhofer ISE on March 7, 2017.
“Whether for mobile communication, computers or LEDs, crystalline materials are key components of our modern lifestyle,” says Dr. Stephan Riepe, group head in the Department of Silicon Materials at Fraunhofer ISE. “Crystal growth has a long tradition and today is still far from becoming obsolete. Materials with special crystalline structure are being developed for applications in high-temperature superconductors through to low-loss power transmission. Artificial diamonds are a favorite choice for building quantum computers. At the conference, the production of silicon, III-V semiconductors and most currently perovskite layers for cost-effective high efficiency tandem solar cells will also be discussed.”
In Freiburg, a close cooperation exists between the Fraunhofer Institutes and the University of Freiburg. For example, at Fraunhofer ISE a doctoral thesis of the University of Freiburg was carried out which investigated how impurities can be minimized during multicrystalline silicon production. In the production process, liquid silicon is melted in a quartz crucible and subsequently solidified. Similar to flour’s function when sprinkled in a baking form, silicon nitride powder acts as a separating agent between the crucible and the silicon. Here the aim is to reduce impurities on the scale of parts per billion, or ppb, to achieve the highest solar cell efficiencies. On a regular basis, student and doctoral degree theses are carried out to address such questions.